Dasatinib: ten years of clinical practice worldwide

Dasatinib: ten years of clinical practice worldwide

The article contains results of meta-analysis of experience in use of second-generation tyrosine kinase inhibitors – dasatinib. The results of clinical trials dasatinib therapy in chronic myelogenous leukemia imatinib-resistant or intolerant patients are presented. The dasatinib and imatinib compara...

Full description

Bibliographic Details
Main Authors:	K. M. Abdulkadyrov, V. A. Shuvaev, I. S. Martynkevich
Format:	Article
Language:	Russian
Published:	ABV-press 2016-03-01
Series:	Онкогематология
Subjects:	dasatinib tyrosine kinase inhibitors chronic myelogenous leukemia philadelphia-positive acute lymphoblastic leukemia bcr-abl treatment free remission
Online Access:	https://oncohematology.abvpress.ru/ongm/article/view/178

Similar Items

Multiple Keratoacanthomas, Philadelphia Chromosome+ Acute Lymphoblastic Leukemia, and Dasatinib: A Case Report
by: Siddhant Thukral, et al.
Published: (2015-11-01)

Successful Preservation of Native BCR::ABL1 in Chronic Myeloid Leukemia Primary Leukocytes Reveals a Reduced Kinase Activity
by: Christian Boni, et al.
Published: (2022-06-01)

A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens
by: Zhen-Yu Xiong, et al.
Published: (2024-12-01)

Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients
by: V. A. Shuvaev, et al.
Published: (2014-07-01)

Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients
by: V. A. Shuvaev, et al.
Published: (2014-07-01)

Use of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia (CML)
by: C. B. Almeida, et al.
Published: (2016-11-01)

Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission
by: V. A. Shuvaev, et al.
Published: (2015-01-01)

Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission
by: V. A. Shuvaev, et al.
Published: (2015-01-01)

Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
by: Asako Takeuchi, et al.
Published: (2021-01-01)

Recommendations from a Portuguese Expert Group for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients in Clinical Practice
by: Antonio Almeida, et al.
Published: (2019-08-01)

Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis
by: Peng Zeng, et al.
Published: (2020-09-01)

Análisis de costo-efectividad de nilotinib, dasatinib e imatinib como terapia de primera línea en leucemia mieloide crónica en Colombia, 2012
by: Martín Romero, et al.
Published: (2014-03-01)

Diversity of breakpoints of variant Philadelphia chromosomes in chronic myeloid leukemia in Brazilian patients
by: Maria de Lourdes Lopes Ferrari Chauffaille, et al.
Published: (2015-02-01)

Association of HLA antigens and BCR-ABL transcripts in leukemia patients with the Philadelphia chromosome
by: Daiana Landenberger de Carvalho, et al.
Published: (2012-01-01)

Serum concentrations of nitrite and malondialdehyde as markers of oxidative stress in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
by: Maria Juracy Petrola, et al.
Published: (2012-01-01)

Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase
by: Ol'ga Yur'evna Vinogradova, et al.
Published: (2009-07-01)

A Case Report of BCR-ABL-JAK2-Positive Chronic Myeloid Leukemia with Complete Hematological and Major Molecular Response to Dasatinib
by: Elrazi Awadelkarim Hamid Ali, et al.
Published: (2021-04-01)

Dasatinib-Induced Colitis in a Patient with Chronic Myelogenous Leukemia
by: David N. Perdigoto, et al.
Published: (2017-10-01)

Exploration of treatment‐free remission in CML, based on molecular monitoring
by: Zhao Zhang, et al.
Published: (2024-01-01)

Cost-effectiveness analysis of dasatinib versus imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia patients in China
by: Wang Cao, et al.
Published: (2022-12-01)

Cost-effectiveness analysis of imatinib versus dasatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia when combined with conventional chemotherapy in China
by: Min Chen, et al.
Published: (2023-06-01)

Trends in mortality of adult patients diagnosed with myeloid leukemia from 1994 to 2011 in southeastern Brazil
by: Fernando Callera, et al.
Published: (2015-02-01)

Variables associated with pulmonary hypertension screened by echocardiography in chronic myeloid leukemia patients on dasatinib therapy
by: Wenying Jin, et al.
Published: (2022-08-01)

Mechanistic Insights Into Co-Administration of Allosteric and Orthosteric Drugs to Overcome Drug-Resistance in T315I BCR-ABL1
by: Hao Zhang, et al.
Published: (2022-03-01)

Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice
by: Carla Boquimpani, et al.
Published: (2022-07-01)

Renal tuberculosis in an imatinib-treated chronic myeloid leukemia
by: Abhilash Chandra, et al.
Published: (2020-04-01)

Long-Term Survival, Vascular Occlusive Events and Efficacy Biomarkers of First-Line Treatment of CML: A Meta-Analysis
by: Hélène Haguet, et al.
Published: (2020-05-01)

Pediatric chronic myeloid leukemia in myeloid blast crisis
by: Biswajit Dey, et al.
Published: (2023-04-01)

Combination chemotherapy plus dasatinib leads to comparable overall survival and relapse‐free survival rates as allogeneic hematopoietic stem cell transplantation in Philadelphia positive acute lymphoblastic leukemia
by: Jeremy Chang, et al.
Published: (2019-06-01)

Cardiotoxicity of Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients
by: Adriatik Berisha, et al.
Published: (2023-02-01)

Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood
by: Hong Hoe Koo
Published: (2011-03-01)

Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations
by: Keskin D, et al.
Published: (2016-10-01)

Which Tyrosine Kinase Inhibitors Should Be Selected as the First-Line Treatment for Chronic Myelogenous Leukemia in Chronic Phase?
by: Takaaki Ono
Published: (2021-10-01)

BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia
by: Gustavo P. Amarante-Mendes, et al.
Published: (2022-01-01)

Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion
by: Hao Zhang, et al.
Published: (2021-07-01)

Isolated monocytosis was the flag preceding abnormalities in other parameters of complete blood counts in chronic myeloid leukemia with e1a2 (minor, P190) chimeric transcripts
by: Jae Won Yun, et al.
Published: (2019-03-01)

Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase: the importance of a major molecular response
by: Melissa Pereira Machado, et al.
Published: (2011-06-01)

Priapism as the first manifestation in chronic myeloid leukemia: A case report and focused review of literature
by: Claudia Lucia Sossa Melo, et al.
Published: (2021-11-01)

Is higher lymphocyte count a potential strategy for preventing chronic kidney disease in patients receiving long-term dasatinib treatment?
by: Hirokazu Nakayama, et al.
Published: (2023-01-01)

Spontaneous Remission in a Patient with Chronic Myeloid Leukemia: A Case Report
by: Awni Alshurafa, et al.
Published: (2023-10-01)